Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 406463, 9 pages
http://dx.doi.org/10.1155/2015/406463
Research Article

A miRNA-Driven Inference Model to Construct Potential Drug-Disease Associations for Drug Repositioning

1School of Software, East China Jiaotong University, Nanchang 330013, China
2Intelligent Optimization & Information Processing Lab, East China Jiaotong University, Nanchang 330013, China
3School of Information Science and Engineering, Central South University, Changsha 410083, China

Received 28 November 2014; Revised 13 January 2015; Accepted 29 January 2015

Academic Editor: Eugenio Ferreira

Copyright © 2015 Hailin Chen and Zuping Zhang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Xie, L. Xie, S. L. Kinnings, and P. E. Bourne, “Novel computational approaches to polypharmacology as a means to define responses to individual drugs,” Annual Review of Pharmacology and Toxicology, vol. 52, pp. 361–379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. T. T. Ashburn and K. B. Thor, “Drug repositioning: identifying and developing new uses for existing drugs,” Nature Reviews Drug Discovery, vol. 3, no. 8, pp. 673–683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. Z. Wu, Y. Wang, and L. Chen, “Network-based drug repositioning,” Molecular BioSystems, vol. 9, no. 6, pp. 1268–1281, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. J. N. Weinstein, T. G. Myers, P. M. O'Connor et al., “An information-intensive approach to the molecular pharmacology of cancer,” Science, vol. 275, no. 5298, pp. 343–349, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Hughes, B. Andrews, and C. Boone, “Old drugs, new tricks: using genetically sensitized yeast to reveal drug targets,” Cell, vol. 116, no. 1, pp. 5–7, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Y. Lum, C. D. Armour, S. B. Stepaniants et al., “Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes,” Cell, vol. 116, no. 1, pp. 121–137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. K. E. Kinnamon and W. E. Rothe, “Biological screening in the U.S. Army antimalarial drug development program,” The American Journal of Tropical Medicine and Hygiene, vol. 24, no. 2, pp. 174–178, 1975. View at Google Scholar · View at Scopus
  9. J. T. Dudley, T. Deshpande, and A. J. Butte, “Exploiting drug-disease relationships for computational drug repositioning,” Briefings in Bioinformatics, vol. 12, no. 4, pp. 303–311, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Keiser, V. Setola, J. J. Irwin et al., “Predicting new molecular targets for known drugs,” Nature, vol. 462, no. 7270, pp. 175–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Eckert and J. Bajorath, “Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches,” Drug Discovery Today, vol. 12, no. 5-6, pp. 225–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Noeske, B. C. Sasse, H. Stark, C. G. Parsons, T. Weil, and G. Schneider, “Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists,” ChemMedChem, vol. 1, no. 10, pp. 1066–1068, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Lamb, E. D. Crawford, D. Peck et al., “The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease,” Science, vol. 313, no. 5795, pp. 1929–1935, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Iorio, R. Bosotti, E. Scacheri et al., “Discovery of drug mode of action and drug repositioning from transcriptional responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14621–14626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Wei, D. Twomey, J. Lamb et al., “Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance,” Cancer Cell, vol. 10, no. 4, pp. 331–342, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Zahler, S. Tietze, F. Totzke et al., “Inverse in silico screening for identification of kinase inhibitor targets,” Chemistry & Biology, vol. 14, no. 11, pp. 1207–1214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. S. L. Kinnings, N. Liu, N. Buchmeier, P. J. Tonge, L. Xie, and P. E. Bourne, “Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis,” PLoS Computational Biology, vol. 5, no. 7, Article ID e1000423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. A. P. Chiang and A. J. Butte, “Systematic evaluation of drug-disease relationships to identify leads for novel drug uses,” Clinical Pharmacology and Therapeutics, vol. 86, no. 5, pp. 507–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Hu and P. Agarwal, “Human disease-drug network based on genomic expression profiles,” PLoS ONE, vol. 4, no. 8, Article ID e6536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Suthram, J. T. Dudley, A. P. Chiang, R. Chen, T. J. Hastie, and A. J. Butte, “Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets,” PLoS Computational Biology, vol. 6, no. 2, Article ID e1000662, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Campillos, M. Kuhn, A.-C. Gavin, L. J. Jensen, and P. Bork, “Drug target identification using side-effect similarity,” Science, vol. 321, no. 5886, pp. 263–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. L. V. Rhodes, A. M. Nitschke, H. C. Segar et al., “The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells,” Oncology Reports, vol. 27, no. 1, pp. 10–16, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Filipowicz, L. Jaskiewicz, F. A. Kolb, and R. S. Pillai, “Post-transcriptional gene silencing by siRNAs and miRNAs,” Current Opinion in Structural Biology, vol. 15, no. 3, pp. 331–341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Krichevsky, K. S. King, C. P. Donahue, K. Khrapko, and K. S. Kosik, “A microRNA array reveals extensive regulation of microRNAs during brain development,” RNA, vol. 9, no. 10, pp. 1274–1281, 2003. View at Google Scholar
  26. A. Esquela-Kerscher and F. J. Slack, “Oncomirs—microRNAs with a role in cancer,” Nature Reviews Cancer, vol. 6, no. 4, pp. 259–269, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. Q. Cui, Z. Yu, E. O. Purisima, and E. Wang, “Principles of microRNA regulation of a human cellular signaling network,” Molecular Systems Biology, vol. 2, article 46, 2006. View at Google Scholar
  28. M. V. G. Latronico, D. Catalucci, and G. Condorelli, “Emerging role of microRNAs in cardiovascular biology,” Circulation Research, vol. 101, no. 12, pp. 1225–1236, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. X. Liu, S. Wang, F. Meng et al., “SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression,” Bioinformatics, vol. 29, no. 3, pp. 409–411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Ling, M. Fabbri, and G. A. Calin, “MicroRNAs and other non-coding RNAs as targets for anticancer drug development,” Nature Reviews Drug Discovery, vol. 12, no. 11, pp. 847–865, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Qiu, G. Chen, and Q. Cui, “Towards the understanding of microRNA and environmental factor interactions and their relationships to human diseases,” Scientific Reports, vol. 2, article 318, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. X. Chen, M.-X. Liu, Q.-H. Cui, and G.-Y. Yan, “Prediction of disease-related interactions between microRNAs and environmental factors based on a semi-supervised classifier,” PLoS ONE, vol. 7, no. 8, Article ID e43425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Zhang, L. Chen, E. J. Jung, and G. A. Calin, “Targeting MicroRNAs with small molecules: from dream to reality,” Clinical Pharmacology and Therapeutics, vol. 87, no. 6, pp. 754–758, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Shomron, “MicroRNAs and pharmacogenomics,” Pharmacogenomics, vol. 11, no. 5, pp. 629–632, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Li, C. Qiu, J. Tu et al., “HMDD v2.0: a database for experimentally supported human microRNA and disease associations,” Nucleic Acids Research, vol. 42, no. 1, pp. D1070–D1074, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. A. P. Davis, C. J. Grondin, K. Lennon-Hopkins et al., “The comparative toxicogenomics database's 10th year anniversary: update 2015,” Nucleic Acids Research, vol. 43, no. 1, pp. D914–D920, 2015. View at Publisher · View at Google Scholar
  37. A. C. Rodrigues, X. Li, L. Radecki et al., “MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines,” Biopharmaceutics & Drug Disposition, vol. 32, no. 6, pp. 355–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Akhtar, Z. Rasheed, S. Ramamurthy, A. N. Anbazhagan, F. R. Voss, and T. M. Haqqi, “MicroRNA-27b regulates the expression of matrix metalloproteinase 13 in human osteoarthritis chondrocytes,” Arthritis and Rheumatism, vol. 62, no. 5, pp. 1361–1371, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. P. K. Busk and S. Cirera, “MicroRNA profiling in early hypertrophic growth of the left ventricle in rats,” Biochemical and Biophysical Research Communications, vol. 396, no. 4, pp. 989–993, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. Q. Jiang, Y. Hao, G. Wang et al., “Prioritization of disease microRNAs through a human phenome-microRNAome network,” BMC Systems Biology, vol. 4, supplement 1, article S2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. M.-X. Liu, X. Chen, G. Chen, Q.-H. Cui, and G.-Y. Yan, “A computational framework to infer human disease-associated long noncoding RNAs,” PLoS ONE, vol. 9, no. 1, Article ID e84408, 2014. View at Publisher · View at Google Scholar · View at Scopus